Paul Tudor Jones Eli Lilly & CO Call Options Transaction History

Tudor Investment Corp Et Al

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$772.14 - $960.02 $6.87 Million - $8.54 Million	8,900 Added 24.45%	45,300 $40.1 Million
Q2 2024 Aug 14, 2024	SELL	$724.87 - $909.04 $29.8 Million - $37.4 Million	-41,100 Reduced 53.03%	36,400 $33 Million
Q1 2024 May 15, 2024	BUY	$592.2 - $792.28 $23.5 Million - $31.5 Million	39,700 Added 105.03%	77,500 $60.3 Million
Q4 2023 Feb 14, 2024	SELL	$525.19 - $619.13 $3.36 Million - $3.96 Million	-6,400 Reduced 14.48%	37,800 $22 Million
Q3 2023 Nov 15, 2023	BUY	$434.7 - $599.3 $14.2 Million - $19.6 Million	32,700 Added 284.35%	44,200 $23.7 Million
Q2 2023 Aug 14, 2023	BUY	$350.74 - $468.98 $1.79 Million - $2.39 Million	5,100 Added 79.69%	11,500 $5.39 Million
Q1 2023 May 15, 2023	BUY	$310.63 - $364.82 $1.99 Million - $2.33 Million	6,400 New	6,400 $2.2 Million

4,007

752M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $760B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.